menu
    • menu
    [{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Spirig Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tibolone","moa":"Sulphatase","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mithra Pharmaceuticals \/ Spirig Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Spirig Healthcare"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tibolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ BioSyent Pharma Inc","highestDevelopmentStatusID":"14","companyTruncated":"Mithra Pharmaceuticals \/ BioSyent Pharma Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Tibolone

    Menu

    Tibolone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mithra Pharmaceuticals

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mithra Pharmaceuticals

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibolone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : BIOSYENT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets

                            Details : BioSyent has acquired intellectual property, global rights, certain licensing, distribution and supply agreements related to Tibelia (tibolone), a prescription hormone replacement therapy.

                            Brand Name : Tibelia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2024

                            Lead Product(s) : Tibolone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : BIOSYENT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mithra Pharmaceuticals

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mithra Pharmaceuticals

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibolone

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Spirig Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland

                            Details : Developed by Mithra as the bioequivalent version of Livial® Tibelia® is a complex oral formulation composed of tibolone. Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia® in Liechtenstein...

                            Brand Name : Tibelia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 11, 2020

                            Lead Product(s) : Tibolone

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Spirig Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth